Moderna Shares Rebound on Promising Vaccine Data
Published on 09/17/2025 at 05:09 | Redaktion boerse-global.deModerna investors have experienced significant volatility recently as the biotech company navigated both concerning safety reports and encouraging clinical developments. The stock’s dramatic movements reflect the market’s ongoing assessment of the company’s position in the evolving vaccine landscape.
The coming weeks present pivotal moments for Moderna, with a Senate hearing scheduled for September 17th followed by CDC advisory meetings on September 18th and 19th. These sessions could yield updated vaccination recommendations ahead of the fall season. Investors will be watching closely for how these developments might influence Moderna’s commercial performance, which will become clearer when the company reports quarterly results in late October.
Strong Immune Response Data Drives Recovery
On Tuesday,... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
